Array Biopharma Inc.

Eli Lilly and Company

Ajay Singh

Steven Armen Boyd

Thomas Daniel Aicher

Kevin Ronald Condroski

Ronald Jay Hinklin

Mark Joseph Chicarelli

Timothy M Turner

John Peter Fischer

Jay Bradford Fell

Eli M Wallace

Indrani W Gunawardana

Rustam Ferdinand Garrey

Michael J Rodriguez

John Gordon Allen

David A Mareska

Frantz Victor

Andrew Caerwyn Williams

Christopher Stanley Galka

Karin Briner

Maria Angeles Martinez-Grau

Michael Philip Cohen

Deyi Zhang

Roger Ryan Rothhaar

Michael Wade Tidwell

Matthew Robert Reinhard

Sarah Lynne Hellman

Josef Roland Bencsik

Christopher Stephen Siedem

Wai-Man Lee

Arundhati S Deo

Scott Alan Pratt

Michael John Rodriguez

Richard Gerard Conway

Timothy Mark Turner

Ferdinand Garrey Rustam

Provided are intermediates having the formulas wherein R, R, and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.

Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives

Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

2-aminopyridine analogs as glucokinase activators

Provided are compounds of Formula (I): wherein R, R, R, L and Dare as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein. 

Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which X, X, L, R, R, R, R, R, R, R, R, and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions. 

Piperidinyl-substituted lactams as GPR119 modulators

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where:

[object Object]

Provided are compounds having the Formula I or salts thereof, wherein R, L, R, R, Dand Rare as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

2-aminopyridine derivatives as glucokinase activators

Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase. 

Provided are compounds of formula I wherein R, L, Z, Y, G and Rare as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

Glucokinase activators

Growing community of inventors

Longmont, CO, United States of America

Ajay Singh